Tech Company Financing Transactions
Protagonist Therapeutics Funding Round
Protagonist Therapeutics secured a $4 million Series B funding round on 9/19/2013. Investors included Pharmstandard.
Transaction Overview
Company Name
Announced On
9/19/2013
Transaction Type
Venture Equity
Amount
$4,000,000
Round
Series B
Investors
Proceeds Purpose
The new funding will support the discovery and development of Protagonist's pipeline of oral di-sulfide rich peptide (DRP) therapeutics that combine the best properties of small molecule drugs and large molecule biologics in a single chemical entity.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
7707 Gateway Blvd. 140
Newark, CA 94560
USA
Newark, CA 94560
USA
Phone
Website
Email Address
Overview
Protagonist Therapeutics (NASDAQ: PTGX) is a biotechnology company pursuing the discovery and development of disulfide-rich peptides (DRPs) as well differentiated alternatives to biologics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dinesh Patel
Chief Financial Officer
Donald Kalkofen
Chief Medical Officer
Samuel Saks
Chief Scientific Officer
David Liu
VP - Bus. Development
Suneel Gupta
VP - Bus. Development
Tracy Woody
Browse more venture capital transactions:
Prev: 9/19/2013: Gigya venture capital transaction
Next: 9/19/2013: Deliv venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs